What to Expect at the Leading Industry Touchpoint for Drug-Diagnostic Co-Development
As the precision medicine field evolves at lightning speed, from liquid biopsy–driven MRD detection and high‑plex single‑cell and multi‑omic profiling to breakthroughs in digital pathology, spatial analytics, and next‑generation IVD assays- this year's upcoming 16th World Clinical Biomarkers & Companion Diagnostics Summit is an unmissable opportunity to uncover the latest translational case studies, global regulatory shifts, and integrated commercialization strategies redefining how biomarkers power drug development, clinical decision‑making, and scalable personalized care.
A Snapshot of Unmissable Agenda Highlights
Bolster Biomarker Discovery & Validation
Uncover cutting-edge progress in genomic sequencing, ctDNA, and MRD biomarkers, empowering earlier detection and real-time disease monitoring
Implement Novel Technologies & Trials
Charter the integration of omics and AI-driven biomarker strategies advancing early detection and personalized therapies across high-burden indications
Pioneer Digital & AI-Enabled Innovations
Discover the workflows, models and adoption strategies behind scalable and physician appropriate digital and computational pathology innovations
Optimize Drug-Diagnostic Co-Development
Explore the initiation, scale-up and regulatory responsibilities of co-development partnerships to spark compliant and scalable strategic alliances
Streamline CDx Development & Commercialization
Discover fit-for-purpose CDx strategies that mitigate testing disparities, reduce clinical setbacks, and strengthen therapeutic development
Navigate IVDR Adherence
Cast your attention to the expectations of global regulatory and notified bodies to streamline harmonized drug-diagnostic compliance and approvals worldwide
Divide & Conquer
The precision medicine field is vast, which is why we have meticulously researched with subject matter experts to identify the key challenges facing the community across indications, biomarkers, biopsy types, testing technologies and drug modalities.
By expanding into 5 end-to-end tracks (Biomarker Discovery & Translational Development, Clinical Biomarker Development and CDx Development & Commercialization, Digital Pathology & Spatial Biomarkers, Multimodal & AI‑Enabled Endpoints), our speakers have tailored their presentations to dive into specific challenges for those stages of development.
By sending different members of the team across the drug pipeline, you can be sure you’ve left no stone unturned and have a team inspired with actionable takeaways to apply to their work.
With a brand-new digital and AI- expansion for 2026, see a preview of our new tracks:
Biomarker Discovery & Translation
Advance epigenetics, multi‑omics integration, high‑plex and complex biomarker panels across oncology and non‑oncology diseases to refine early‑phase signal detection and patient stratification
Clinical & CDx
Development
Strengthen biomarker‑driven trial design, global enrolment, IVD validation, novel endpoint integration for regulatory compliant Rx-Dx co‑development
Rx–Dx Commercialization & Adoption
Navigate coverage shifts, international payer evidence needs, pricing and launch sequencing to enable scalable, equitable, and regionally aligned diagnostic access at therapeutic launch
Digital Pathology & Spatial Biomarkers (NEW)
Unlock digital pathology, spatial transcriptomic biomarkers and cloud integrated workflows, standardization and automation to enhance diagnostic accuracy, throughput, and reproducibility
Multimodal & AI‑Enabled Endpoints (NEW)
Advance multimodal biomarkers, integrated, ML‑derived response predictors, and emerging endpoints to deliver earlier, more precise measures of clinical benefit
Register your Interest for 2026
- Free* to Attend for Biopharma & Academia
- The Globes Leading Biomarker & Companion Diagnostic Forum
- Strategic Rx-Dx Co-Development & Partnership Selection Panels
- Biomarker panels in Oncology, Haematology, Neurological, Chronic, Autoimmune, & Rare Disease
- Brand New Case Studies on Digital Pathology, Multimodal Data and AI-Enabled Precision Medicine
- Exclusive Networking & Partnerships Opportunities
Attending Companies Included
Explore the Agenda
Hear the latest translational, clinical and post-approval breakthroughs and gain exclusive insights into precision medicine innovations during our packed agenda, interactive roundtables, and new drug-diagnostic partnerships panel discussions
Partner With Us
Position yourself alongside other leading IVD and CDx solution providers to ensure your brand is at the heart of precision medicines deals and collaborations
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning a range of precision therapy modalities and indications, and make critical connections during our dedicated networking sessions